Osmar Kenji Yagi

Osmar Kenji Yagi

Auto-generated profile, based on publicly available information

Osmar Kenji Yagi

Instituto do Câncer do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo)
Verified
Journal Article
Open access
PDF file
LBLeandro Cardoso Barchi
Leandro Cardoso Barchi
Marcus F. Kodama P. RamosMarcus F. Kodama P. Ramos
Marcus F. Kodama P. Ramos
OYOsmar Kenji Yagi
Osmar Kenji Yagi
DMDonato Roberto Mucerino
Donato Roberto Mucerino
CBClaudio José Caldas Bresciani
Claudio José Caldas Bresciani
WJWilson Rodrigues de Freitas Júnior
Wilson Rodrigues de Freitas Júnior
Background: The II Brazilian Consensus on Gastric Cancer by the Brazilian Gastric Cancer Association (ABCG) was recently published. On this occasion, several experts in gastric cancer expressed their opinion before the statements presented. Aim: To present the ABCG Guidelines (part 1) regarding the diagnosis, staging, endoscopic treatment and follow-up of gastric cancer patients. Methods: To forge these Guidelines, the authors carried out an extensive and current review regarding each statement present in the II Consensus, using the Medline/PubMed, Cochrane Library and SciELO databases with the following descriptors: gastric cancer, staging, endoscopic treatment and follow-up. In addition, each statement was classified according to the level of evidence and degree of recommendation. Results: Of the 24 statements, two (8.3%) were classified with level of evidence A, 11 (45.8%) with B and 11 (45.8%) with C. As for the degree of recommendation, six (25%) statements obtained grade of recommendation 1, nine (37.5%) recommendation 2a, six (25%) 2b and three (12.5%) grade 3. Conclusion: The guidelines presented here are intended to assist professionals working in the fight against gastric cancer with relevant and current information, granting them to be applied in the daily medical practice.

30 December 2024 in BJS Open
Verified
Journal Article
Open access
Marcus F. Kodama P. RamosMarcus F. Kodama P. Ramos
Marcus F. Kodama P. Ramos
Marina Alessandra PereiraMarina Alessandra Pereira
Marina Alessandra Pereira
ADAndré Roncon Dias
André Roncon Dias
OYOsmar Kenji Yagi
Osmar Kenji Yagi
BZBruno Zilberstein
Bruno Zilberstein
URUlysses Ribeiro-Junior
Ulysses Ribeiro-Junior
Background: Gastric outlet obstruction due to unresectable tumours is usually managed with a gastrojejunostomy. Unfortunately, the unsatisfactory outcomes of this procedure have led to the search for alternatives, including gastric partitioning. Methods: Monocentric, randomized, parallel, open-label trial that included patients with obstructive, unresectable distal gastric tumours. The objective was to compare gastric partitioning to gastrojejunostomy, considering the gastric outlet obstruction scoring system scale as the main outcome. Randomization was performed using computer-generated software available online and after the application of the informed consent term, the allocation group was revealed to the surgeon before the surgical procedure. Results: Over 7 years, 90 patients were initially randomized. After applying the inclusion and exclusion criteria, 25 patients were included in the gastrojejunostomy group and 27 in the partitioning group. Both groups were similar regarding initial clinical characteristics including sex, age, weight, clinical performance, and the acceptance of oral diet. Surgery duration, length of hospital stay, postoperative complications, and 30- and 90-day mortality rates were similar between groups. Acceptance of normal diet was more frequently reached by patients in the partitioning group (96% versus 72%; P = 0.022). During outpatient follow-up, maintenance of oral intake and weight was similar between groups. Patients in the partitioning group received more frequent red blood cell transfusions (81% versus 52%; P = 0.024). There was no difference regarding the administration of palliative chemotherapy lines and survival. In the multivariable analysis, the inability to eat a full diet (P = 0.035) and the absence of palliative chemotherapy after the procedure (P = 0.001) were associated with worse survival. Conclusions: Gastric partitioning provided a better return of the ability to accept food orally. There was no difference regarding postoperative complications and long-term survival. Trial registration: NCT02065803, clinicaltrials.gov

1 January 2020 in ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo)
Verified
Journal Article
Open access
PDF file
ADAndre Roncon Dias
Andre Roncon Dias
Marcus F. Kodama P. RamosMarcus F. Kodama P. Ramos
Marcus F. Kodama P. Ramos
DSDaniel José Szor
Daniel José Szor
RARicardo Abdalla
Ricardo Abdalla
LBLeandro Barchi
Leandro Barchi
ICIvan Cecconello
Ivan Cecconello
Background: Robotic gastrectomy is gaining popularity worldwide. It allows reduced blood loss and lesser pain. However, it widespread use is limited by the extensive learning curve and costs. Aim: To describe our standard technique with reduced use of robotic instruments. Methods: We detail the steps involved in the procedure, including trocar placement, necessary robotic instruments, and meticulous surgical description. Results: After standardizing the procedure, 28 patients were operated with this budget technique. For each procedure material used was: 1 (Xi model) or 2 disposable trocars (Si) and 4 robotic instruments. Stapling and clipping were performed by the assistant through an auxiliary port, limiting the use of robotic instruments and reducing the cost. Conclusion: This standardization helps implementing a robotic program for gastrectomy in the daily practice or in one`s institution.

21 November 2025 in Clinics
Verified
Journal Article
Open access
Marcus F. Kodama P. RamosMarcus F. Kodama P. Ramos
Marcus F. Kodama P. Ramos
Marina Alessandra PereiraMarina Alessandra Pereira
Marina Alessandra Pereira
ADAndre Roncon Dias
Andre Roncon Dias
OYOsmar Kenji Yagi
Osmar Kenji Yagi
BNBruna de Camargo Nigro
Bruna de Camargo Nigro
URUlysses Ribeiro-Junior
Ulysses Ribeiro-Junior
The treatment of Gastric Cancer (GC) has evolved with advances in multimodal therapy and minimally invasive surgery. This study aimed to provide an overview of the current treatment and survival outcomes of GC at a public high-volume cancer center during 15 years. Patients with gastric adenocarcinoma who underwent any surgical procedure between January 2009 and December 2023 were retrospectively included. To investigate temporal differences in patient characteristics and therapeutic approaches, the case cohort was divided into two time periods: Period I (2009-2016) and II (2016-2023). A total of 1406 patients were included: 741 (52.7 %) were treated in Period I, and 665 (47.3 %) in Period II. The proportion of curative-intent surgeries remained stable (65.2% vs. 65.1), but diagnostic procedures increased (7.3 % vs. 12.2). Overall, 804 (57.2 %) patients underwent potentially curative gastrectomy. In Period II, patients had advanced ASA scores, more advanced clinical staging, and more frequent D1 lymphadenectomy (all p < 0.05). The use of minimally invasive surgery and the number of resected lymph nodes increased (both p < 0.001). Multimodal treatment became more frequent, with increased use of preoperative chemotherapy (p = 0.03). There were no significant differences in postoperative complications or 30- and 90-day mortality rates between the two periods. In multivariable analysis, advanced age, ASA III/IV, total gastrectomy, D1 lymphadenectomy, diffuse/mixed histology, advanced pT stage, and lymph node metastasis were independent factors associated with worse survival (all p < 0.05). Over 15 years, treatment evolved toward increased use of minimally invasive and multimodal approaches, with no impact on short-term surgical outcomes.

1 January 2025 in ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo)
Verified
Journal Article
Open access
MRMateus Barradas Ribeiro
Mateus Barradas Ribeiro
Marina Alessandra PereiraMarina Alessandra Pereira
Marina Alessandra Pereira
DMDonato Roberto Mucerino
Donato Roberto Mucerino
OYOsmar Kenji Yagi
Osmar Kenji Yagi
ADAndré Roncon Dias
André Roncon Dias
Marcus F. Kodama P. RamosMarcus F. Kodama P. Ramos
Marcus F. Kodama P. Ramos
Background: Gastric neuroendocrine tumors (gNETs) are uncommon neoplasms arising from enterochromaffin-like cells, representing a distinct subset of gastric malignancies, with challenging clinical management. Aims: To analyse the classification, treatment indication, and survival of patients diagnosed with gNETs. Methods: We retrospectively analyzed patients diagnosed with gNETs between 2009 and 2025 at a high-volume tertiary center in Brazil. Clinical, pathological, and treatment data were reviewed, and tumors were classified according to World Health Organization and clinicopathological criteria into Types I, II, and III. Results: Of the 75 patients included, 53 (70.7%) were classified as Type I, 5 (6.7%) as Type II, and 17 (22.6%) as Type III. Treatment included surgery in 25 patients (33.3%) and endoscopic resection in 50 (66.7%). Type I tumors predominated in females (p<0.001), were frequently multifocal (p<0.001), associated with higher body mass index (p=0.002), and were mainly managed endoscopically (p=0.008). Type II tumors were rare and associated with multiple endocrine neoplasia Type 1, while Type III tumors were predominantly male, larger, high-grade (G3), and frequently metastatic, requiring surgical resection and palliative therapy. Among the 25 surgically treated patients, most were men (52%) and included 12 patients (48.0%) with Type I, 3 (12.0%) with Type II, and 10 (40.0%) with Type III tumors. Survival analysis showed significantly worse outcomes for Type III and G3 tumors. Multivariable analysis identified advanced age (hazards ratio 4.11; 95% confidence interval (95%CI): 1.14–14.80; p=0.030) and tumor, lymph node, metastasis (TNM) stage III/IV (HR 5.42; 95%CI: 1.26–23.26; p=0.023) as independent predictors of poorer survival. Conclusions: gNETs exhibit heterogeneous clinical behavior, with Type I tumors predominating in the Brazilian population. Tumor type, grade, and TNM stage are critical determinants of prognosis and should guide individualized treatment strategies.

11 November 2017 in Arquivos Brasileiros de Cirurgia Digestiva Express
Verified
Journal Article
Open access
Marina Alessandra PereiraMarina Alessandra Pereira
Marina Alessandra Pereira
Marcus F. Kodama P. RamosMarcus F. Kodama P. Ramos
Marcus F. Kodama P. Ramos
SFShiela Faraj
Shiela Faraj
OYOsmar Yagi
Osmar Yagi
ADAndre Dias
Andre Dias
UJUlysses Junior
Ulysses Junior